Milano, September 6th, 2021 - Olon is delighted to announce a major expansion of its Italian site located in Settimo Torinese, which is a historical asset of the global manufacturing network of the Group and moreover represents a centre of excellence for biotechnological manufacturing. The expansion is a key milestone for the site and a cornerstone of the Company strategy that is fostering the development of its biotechnological platform, both in terms of expertise and production capacity.
Olon will build and operate the new area with advanced technologies that, relying on the deep expertise in biomanufacturing, will produce proteins following innovative and highly sustainable processes. Microbial fermentation is one of the most eco-friendly and sustainable technology.
The expansion will allow Olon to increase its capacity to accommodate new and existing clients’ needs, it fits in the strategy of expanding the CDMO services in different market segments. “We are significatively investing in our fermentation capacity following market trends that show an increased demand for microbial bio-manufactured compounds. Offering our expertise in CDMO services and biotechnological platforms as well, we are able to support innovative biotech companies to accelerate the development of new products, combining it with a more sustainable manufacturing approach” explains Paolo Tubertini, CEO at Olon Group. “We are fully committed to understand and meet our customers’ needs, as we continuously seek to provide new capacity and services.”
Thanks to this investment the site of Settimo Torinese will offer the production capacity for the significant volumes needed to sustain the launch of new products.
Relying on an experience gained over more than 50 years, Olon Biotechnology Centres represents one of the most extensive know-how of microbial fermentation in Europe. Expertise and competence are combined with great flexibility at different levels related to the knowledge of various microorganisms and fermentation processes. Flexibility also reflects in the isolation and purification steps because they can rely on 20 different downstream plants. Furthermore, Biotechnology Centres can count on outstanding internal engineering capabilities and expertise. The global footprint led Olon to be one of the leaders in producing via microbial fermentation for third parties globally, thanks to our size and the overall production capacity - 4,500m3.
With a 2020’s Turnover of 530 Mio$, OLON supplies 34 Chemical Intermediates and more than 295 APIs for the Generic market.
Thanks to all the 2.200 employees, and to highly qualified R&D team – more than 200 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological processes, all of them under a full cGMP and regulatory coverage – holder of about 160 active US DMFs and 79 granted CoS.
Always considering human safety and environmental security, OLON handles different and not-common manufacturing process technologies, such as Fluorination, Carbonylation, and Fermentation – combined with chemical synthesis to produce APIs for the majority, proteins, high-value small molecules & microorganisms (application in pharma), food, feed, and other bio-industrial markets.
Headquartered in Rodano (Milan, Italy), OLON has 11 manufacturing facilities - 8 located in Italy, 1 in Spain, 1 in USA and 1 in India, designed in compliance with the strictest international requirements, and 3 branch offices in Hamburg (Germany), Florham Park NJ (USA) and Shanghai (China).
The manufacturing sites are regularly inspected by the most important national and international Authorities, and regularly audited by our partners and customers. The facilities are FDA-inspected and self-identified under GDUFA.
Besides pharmaceutical certifications, OLON complies with ISO standards (14001), has dedicated areas for food-grade manufacturing and complies with Kosher, Halal and within 2018-Q3 also with FSSC 22.000.
To be highlighted OLON’s growing cooperation with Universities: University of Milan (Italy), Milan Politecnico (Italy), University of Pavia (Italy), University of Murcia (Spain), and PROMIDIS (Milan University spin-off).
email@example.com – mobile 338.6674289
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Olon is an Italian company world leader in the Active Pharmaceutical Ingredients (APIs) production, using synthetic and biological processes for Generic market as well as in Contract Development and Manufacturing (CDMO).
Headquartered in Rodano (Italy), Olon has 11 manufacturing facilities – 8 located in Italy, 1 in Spain, 1 in USA and 1 in India, all compliant with international requirements, and 3 branch offices.
Olon offers complete integrated packages and services to support the full development of APIs based on strong knowledge in both, Chemical and Biological processes, in a full cGMPs environment including a complete regulatory coverage.